Table 2.
Renal function and hemodynamics with BNP, URO, and CRRL269
| Natriuretic Peptide Infusion |
|||||||
|---|---|---|---|---|---|---|---|
| Variable | Peptides | Baseline | Low dose | High dose | Washout | Recovery 1 | Recovery 2 |
| UV, ml/min | BNP | 0.13 ± 0.01 | 0.23 ± 0.04 | 0.41 ± 0.06* | 0.45 ± 0.05* | 0.32 ± 0.03* | 0.27 ± 0.03* |
| URO | 0.15 ± 0.01 | 0.24 ± 0.01 | 1.07 ± 0.17*† | 0.65 ± 0.04* | 0.35 ± 0.05 | 0.28 ± 0.03 | |
| CRRL269 | 0.11 ± 0.01 | 0.18 ± 0.03 | 1.19 ± 0.32*† | 1.30 ± 0.29*†# | 0.75 ± 0.14* | 0.39 ± 0.17 | |
| UNaV, µEq/min | BNP | 16.3 ± 6.0 | 45.6 ± 10.8 | 112.9 ± 20.9* | 140.2 ± 21.9* | 93.5 ± 13.4* | 63.4 ± 12.0* |
| URO | 14.2 ± 3.9 | 45.4 ± 12.9 | 203.0 ± 38.6* | 140.6 ± 14.0* | 75.8 ± 10.8* | 57.4 ± 9.5 | |
| CRRL269 | 11.5 ± 3.8 | 31.0 ± 1.81 | 230.2 ± 59.5*† | 283.9 ± 55.7*†# | 180.2 ± 28.9*# | 90.5 ± 9.7 | |
| GFR, ml/min | BNP | 54.5 ± 14.3 | 61.6 ± 18.9 | 55.5 ± 12.7 | 48.0 ± 7.4 | 47.2 ± 6.9 | 57.5 ± 5.5 |
| URO | 38.1 ± 8.9 | 60.6 ± 8.8 | 45.3 ± 8.4 | 43.7 ± 9.7 | 60.8 ± 10.9 | 51.4 ± 7.5 | |
| CRRL269 | 28.1 ± 4.3 | 41.5 ± 11.4 | 69.5 ± 9.5* | 53.1 ± 5.8 | 53.1 ± 8.7 | 65.9 ± 10.8* | |
| RBF, ml/min | BNP | 252.7 ± 26.3 | 254.5 ± 24.4 | 336.7 ± 14.4* | 335.0 ± 16.0* | 305.0 ± 17.4* | 302.4 ± 18.5 |
| URO | 235.0 ± 26.0 | 256.5 ± 30.8 | 306.1 ± 36.6* | 308.8 ± 32.1* | 310.4 ± 36.0* | 293.5 ± 39.8* | |
| CRRL269 | 254.1 ± 34.2 | 258.1 ± 36.1 | 319.0 ± 56.3* | 364.8 ± 58.0* | 355.1 ± 50.9* | 349.5 ± 43.6* | |
| MAP, mmHg | BNP | 124.9 ± 4.4 | 113.8 ± 3.4* | 92.3 ± 2.5* | 97.2 ± 2.7* | 99.3 ± 5.0* | 99.4 ± 5.5* |
| URO | 114.8 ± 4.5 | 107.2 ± 2.7 | 84.8 ± 4.2* | 87.6 ± 3.1* | 89.4 ± 4.1* | 95.7 ± 4.4* | |
| CRRL269 | 118.1 ± 3.8 | 116.8 ± 8.6 | 103.8 ± 9.1* | 101.4 ± 7.8* | 103.3 ± 6.0* | 105.5 ± 6.7* | |
| PCWP, mmHg | BNP | 6.5 ± 0.6 | 5.5 ± 0.6* | 3.4 ± 0.3* | 2.9 ± 0.04* | 3.2 ± 0.5* | 3.9 ± 0.5* |
| URO | 5.7 ± 0.9 | 4.7 ± 1.1 | 3.0 ± 0.7* | 2.7 ± 0.6* | 3.2 ± 0.7* | 3.5 ± 0.9* | |
| CRRL269 | 6.6 ± 0.3 | 5.5 ± 0.6* | 3.0 ± 0.4* | 2.8 ± 0.4* | 3.2 ± 0.4* | 3.6 ± 0.5* | |
| CO, l/min | BNP | 3.8 ± 0.1 | 4.2 ± 0.2* | 4.5 ± 0.2* | 3.7 ± 0.1 | 3.2 ± 0.1* | 3.2 ± 0.1* |
| URO | 3.7 ± 0.3 | 3.7 ± 0.2 | 3.7 ± 0.3 | 3.3 ± 0.3 | 3.2 ± 0.3 | 3.2 ± 0.2 | |
| CRRL269 | 4.1 ± 0.4 | 4.8 ± 0.4 | 5.0 ± 0.5*# | 4.1 ± 0.5 | 3.7 ± 0.3 | 3.7 ± 0.2 | |
| SVR, mmHg·l−1·min−1 | BNP | 32.0 ± 1.5 | 26.6 ± 1.4* | 20.0 ± 1.0* | 25.8 ± 1.0* | 30.5 ± 1.5 | 30.8 ± 1.7 |
| URO | 30.5 ± 1.7 | 28.1 ± 1.0 | 23.0 ± 1.4* | 26.5 ± 1.7 | 27.6 ± 1.7 | 29.4 ± 1.3 | |
| CRRL269 | 29.2 ± 2.9 | 24.1 ± 2.0 | 20.6 ± 1.7* | 25.3 ± 3.2 | 27.9 ± 2.4 | 28.3 ± 2.6 | |
Data are expressed as means ± SE. Absolute values of key parameters after infusion of low-dose 2 pmol·kg−1·min−1 and high-dose 33 pmol·kg−1·min−1 B-type natriuretic peptide (BNP), urodilatin (URO), or CRRL269 in normal canines. Low dose, infusion of low-dose 2 pmol·kg−1·min−1 BNP, URO, or CRRL269; High dose, infusion of high-dose 33 pmol·kg−1·min−1; Washout, 0–30 min postinfusion; Recovery 1 = 30–60 min postinfusion; Recovery 2 = 60–90 min postinfusion. UV, urinary flow; UNaV, urinary sodium excretion; GFR, glomerular filtration rate; RBF, renal blood flow; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; CO, cardiac output; SVR, systemic vascular resistance.
P < 0.05, vs. baseline (one-way ANOVA and Dunnett posttests),
P < 0.05, vs. BNP,
P < 0.05, vs. URO (two-way ANOVA and Bonferroni post hoc tests).